These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 21664089

  • 1. Investigation and structural elucidation of a process related impurity in candesartan cilexetil by LC/ESI-ITMS and NMR.
    Raman B, Sharma BA, Mahale G, Singh D, Kumar A.
    J Pharm Biomed Anal; 2011 Sep 10; 56(2):256-63. PubMed ID: 21664089
    [Abstract] [Full Text] [Related]

  • 2. Identification and characterization of potential impurities of valsartan, AT1 receptor antagonist.
    Sampath A, Reddy AR, Yakambaram B, Thirupathi A, Prabhakar M, Reddy PP, Reddy VP.
    J Pharm Biomed Anal; 2009 Oct 15; 50(3):405-12. PubMed ID: 19560892
    [Abstract] [Full Text] [Related]

  • 3. LC and LC-MS/TOF studies on stress degradation behaviour of candesartan cilexetil.
    Mehta S, Shah RP, Priyadarshi R, Singh S.
    J Pharm Biomed Anal; 2010 Jul 08; 52(3):345-54. PubMed ID: 19505786
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Investigation of amodiaquine bulk drug impurities by liquid chromatography/ion trap mass spectrometry.
    Dongre VG, Karmuse PP, Ghugare PD, Kanojiya SK, Rawal S.
    Rapid Commun Mass Spectrom; 2008 Jul 08; 22(14):2227-33. PubMed ID: 18543378
    [Abstract] [Full Text] [Related]

  • 6. Identification, characterization and quantification of a new impurity in deferasirox active pharmaceutical ingredient by LC-ESI-QT/MS/MS.
    Thomas S, Chandra Joshi S, Vir D, Agarwal A, Rao RD, Sridhar I, Xavier CM, Mathela CS.
    J Pharm Biomed Anal; 2012 Apr 07; 63():112-9. PubMed ID: 22361658
    [Abstract] [Full Text] [Related]

  • 7. Characterization of conjugated metabolites of a new angiotensin II receptor antagonist, candesartan cilexetil, in rats by liquid chromatography/electrospray tandem mass spectrometry following chemical derivatization.
    Kondo T, Yoshida K, Yoshimura Y, Motohashi M, Tanayama S.
    J Mass Spectrom; 1996 Aug 07; 31(8):873-8. PubMed ID: 8799313
    [Abstract] [Full Text] [Related]

  • 8. Highly efficient, selective, sensitive and stability indicating RP-HPLC-UV method for the quantitative determination of potential impurities and characterization of four novel impurities in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI-IT/MS/MS.
    Thomas S, Bharti A, Maddhesia PK, Shandilya S, Agarwal A, Dharamvir, Biswas S, Bhansal V, Gupta AK, Tewari PK, Mathela CS.
    J Pharm Biomed Anal; 2012 Mar 05; 61():165-75. PubMed ID: 22178334
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Identification, isolation, synthesis and characterization of impurities of quetiapine fumarate.
    Bharathi Ch, Prabahar KJ, Prasad ChS, Srinivasa Rao M, Trinadhachary GN, Handa VK, Dandala R, Naidu A.
    Pharmazie; 2008 Jan 05; 63(1):14-9. PubMed ID: 18271296
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Separation and characterization of synthetic impurities of triclabendazole by reversed-phase high-performance liquid chromatography/electrospray ionization mass spectrometry.
    Zhou H, Tai Y, Sun C, Pan Y.
    J Pharm Biomed Anal; 2005 Feb 07; 37(1):97-107. PubMed ID: 15664748
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Characterization of impurities in semi-synthetic vinorelbine bitartrate by HPLC-MS with mass spectrometric shift technique.
    Cao X, Tai Y, Sun C, Wang K, Pan Y.
    J Pharm Biomed Anal; 2005 Sep 01; 39(1-2):39-45. PubMed ID: 16085133
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.